Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Formation Bio is a next-generation pharmaceutical company that leverages artificial intelligence, modern software, and a diverse team of experts to develop its own pipeline of medicines. By integrating technology at every stage of the drug development process, from discovery to clinical trials and commercialization, Formation Bio aims to drastically reduce the time and cost associated with bringing new therapies to patients. The company was formerly the drug development arm of TrialSpark.
Serves as the central hub for strategic decision-making, research and development oversight, software engineering, clinical operations management, and corporate functions.
Modern office space designed to foster collaboration and innovation, likely featuring open-plan areas, advanced technology infrastructure, and versatile meeting spaces.
Characterized by a fast-paced, innovative, and mission-driven environment, blending talent from technology, data science, and pharmaceutical industries. Emphasis on cross-functional collaboration and agile problem-solving.
Located in New York City, a major global center for finance, technology, and an expanding biotechnology ecosystem, providing access to top talent, investment opportunities, and strategic partnerships.
While its physical headquarters is in the United States, Formation Bio operates with a global mindset. This is evident in its talent acquisition strategies, which include remote team members from various countries, and its potential to conduct clinical trials internationally to reach diverse patient populations. Its technology platform is designed for distributed collaboration and data management, supporting global R&D efforts.
450 W 15th Street
New York
NY
USA
Address: N/A
Focus on talent acquisition and operational flexibility rather than maintaining multiple physical regional offices. This allows global talent engagement for specialized roles in drug development and technology.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Formation Bio' leadership includes:
Formation Bio has been backed by several prominent investors over the years, including:
Formation Bio has significantly strengthened its executive leadership over the past 12 months with strategic hires in key areas such as clinical development, finance, and commercial & legal affairs, positioning the company for accelerated growth and pipeline advancement. No major executive departures have been publicly announced during this period.
Discover the tools Formation Bio uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Formation Bio likely utilizes standard professional email address formats. The most common patterns for tech and biotech companies include [first].[last]@formationbio.com or [first_initial][last]@formationbio.com.
[first].[last]@formationbio.com
Format
jane.doe@formationbio.com
Example
85%
Success rate
Formation Bio Newsroom / Business Wire • February 1, 2024
Formation Bio announced the appointment of Gavin Corcoran, MD, FACP, FIDSA, as its new Chief Development Officer. Dr. Corcoran, an experienced leader in drug development, will spearhead the company's clinical development strategies and execution for its growing pipeline of AI-discovered drug candidates....more
Formation Bio Newsroom / PR Newswire • January 8, 2024
Formation Bio and Sanofi have entered into a strategic collaboration to advance the clinical development of amlitelimab, a potential first-in-class monoclonal antibody targeting OX40-Ligand, for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Formation Bio will leverage its AI-powered platform to accelerate Phase 3 trial execution....more
Formation Bio Newsroom • May 24, 2023
Formation Bio officially launched, having previously operated as the drug development arm of TrialSpark. The company secured $116 million in committed capital from leading investors including Andreessen Horowitz, Thrive Capital, and Coatue, to build and advance its own pipeline of drug candidates using its AI-driven drug development platform....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Formation Bio, are just a search away.